HCW Biologics EBIT

HCW Biologics (HCWB) currently reports a EBIT of $-9.1M as of March 2026. That compares with $-12M in the prior-year period — up 25.4% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore HCW Biologics's EBIT history and peer comparisons.

HCW Biologics's EBIT increased from $-12M to $-9.1M — a 25.4% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

HCW Biologics's EBIT of $-9.1M is lower than the Healthcare sector average of $23B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

HCW Biologics reported $-9.1M in EBIT as of March 2026. That compares with $-12M in the prior-year period — up 25.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-9.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for HCW Biologics, and consider following HCWB for alerts when major investors trade the stock.